CO2020012060A2 - Inhibidores de la arginasa - Google Patents
Inhibidores de la arginasaInfo
- Publication number
- CO2020012060A2 CO2020012060A2 CONC2020/0012060A CO2020012060A CO2020012060A2 CO 2020012060 A2 CO2020012060 A2 CO 2020012060A2 CO 2020012060 A CO2020012060 A CO 2020012060A CO 2020012060 A2 CO2020012060 A2 CO 2020012060A2
- Authority
- CO
- Colombia
- Prior art keywords
- compounds
- arginase inhibitors
- arg2
- arg1
- inhibitors
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 102000004452 Arginase Human genes 0.000 title 1
- 108700024123 Arginases Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 102100021723 Arginase-1 Human genes 0.000 abstract 2
- 102100030356 Arginase-2, mitochondrial Human genes 0.000 abstract 2
- 101000752037 Homo sapiens Arginase-1 Proteins 0.000 abstract 2
- 101000792835 Homo sapiens Arginase-2, mitochondrial Proteins 0.000 abstract 2
- 101000800287 Homo sapiens Tubulointerstitial nephritis antigen-like Proteins 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000002194 synthesizing effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862638412P | 2018-03-05 | 2018-03-05 | |
| PCT/US2019/020507 WO2019173188A1 (en) | 2018-03-05 | 2019-03-04 | Arginase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2020012060A2 true CO2020012060A2 (es) | 2021-01-18 |
Family
ID=67847429
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2020/0012060A CO2020012060A2 (es) | 2018-03-05 | 2020-09-29 | Inhibidores de la arginasa |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US12054500B2 (https=) |
| EP (1) | EP3761992A4 (https=) |
| JP (1) | JP7402167B2 (https=) |
| KR (1) | KR102656571B1 (https=) |
| CN (1) | CN111818928A (https=) |
| AU (1) | AU2019229978B2 (https=) |
| BR (1) | BR112020017604A2 (https=) |
| CA (1) | CA3091805A1 (https=) |
| CL (1) | CL2020002271A1 (https=) |
| CO (1) | CO2020012060A2 (https=) |
| CR (1) | CR20200445A (https=) |
| EA (1) | EA202092086A1 (https=) |
| IL (1) | IL276813B2 (https=) |
| MX (1) | MX2020009290A (https=) |
| MY (1) | MY205512A (https=) |
| PE (1) | PE20210452A1 (https=) |
| PH (1) | PH12020551352A1 (https=) |
| SG (1) | SG11202008113RA (https=) |
| UA (1) | UA127897C2 (https=) |
| WO (1) | WO2019173188A1 (https=) |
| ZA (1) | ZA202006006B (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018227187A1 (en) * | 2017-06-09 | 2018-12-13 | The Regents Of The University Of California | Catheter injectable cyclic peptide pro-gelators for myocardial tissue engineering |
| EP3765006A4 (en) | 2018-03-13 | 2022-02-23 | Merck Sharp & Dohme Corp. | ARGINASE INHIBITORS AND METHODS OF USE |
| EP3810615B1 (en) * | 2018-06-20 | 2026-01-28 | Merck Sharp & Dohme LLC | Arginase inhibitors and methods of use |
| ES3034676T3 (en) | 2018-11-16 | 2025-08-21 | Arcus Biosciences Inc | Inhibitors of arg1 and/or arg2 |
| US12240867B2 (en) | 2018-12-18 | 2025-03-04 | Merck Sharp & Dohme Llc | Arginase inhibitors and methods of use |
| AU2021292195A1 (en) | 2020-06-17 | 2023-01-05 | Arcus Biosciences, Inc. | Crystalline forms of a CD73 inhibitor and uses thereof |
| TW202228720A (zh) | 2020-12-22 | 2022-08-01 | 波蘭商昂科艾倫迪治療法股份公司 | 精胺酸酶抑制劑及其使用方法 |
| WO2023077046A1 (en) | 2021-10-29 | 2023-05-04 | Arcus Biosciences, Inc. | Inhibitors of hif-2alpha and methods of use thereof |
| CA3256561A1 (en) | 2022-05-02 | 2023-11-09 | Arcus Biosciences, Inc. | Anti-tigit antibodies and their uses |
| EP4554680A1 (en) | 2022-07-15 | 2025-05-21 | Arcus Biosciences, Inc. | Inhibitors of hpk1 and methods of use thereof |
| US20260028336A1 (en) | 2022-07-20 | 2026-01-29 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| CN119768155A (zh) | 2022-09-14 | 2025-04-04 | 艾库斯生物科学有限公司 | 依曲地南的分散体 |
| WO2024081385A1 (en) | 2022-10-14 | 2024-04-18 | Arcus Biosciences, Inc. | Hpk1 inhibitors and methods of use thereof |
| EP4604920A1 (en) | 2022-10-20 | 2025-08-27 | Arcus Biosciences, Inc. | Lyophilized formulations of cd73 compounds |
| EP4705292A1 (en) | 2023-05-05 | 2026-03-11 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| US20250011318A1 (en) | 2023-05-25 | 2025-01-09 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| WO2025076299A1 (en) | 2023-10-06 | 2025-04-10 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| WO2025193759A1 (en) | 2024-03-12 | 2025-09-18 | Gilead Sciences, Inc. | Solid forms of an azolopyrimidine compound |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5952294A (en) | 1996-07-31 | 1999-09-14 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Peptidyl prodrugs and methods of making and using the same |
| WO1999019295A1 (en) | 1997-10-10 | 1999-04-22 | Trustees Of The University Of Pennsylvania | Compositions and methods for inhibiting arginase activity |
| WO2002089739A2 (en) | 2001-05-09 | 2002-11-14 | Newbiotics, Inc. | Peptide deformylase activated prodrugs |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| AU2006230099B2 (en) | 2005-03-25 | 2012-04-19 | Gitr, Inc. | GITR binding molecules and uses therefor |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| ATE524466T1 (de) | 2007-07-03 | 2011-09-15 | Actelion Pharmaceuticals Ltd | 3-azabicycloä3.3.0üoktanverbindungen |
| ES2776406T3 (es) | 2007-07-12 | 2020-07-30 | Gitr Inc | Terapias de combinación que emplean moléculas de enlazamiento a GITR |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| AU2009210570B2 (en) | 2008-01-30 | 2014-11-20 | Indiana University Research And Technology Corporation | Ester-based insulin prodrugs |
| CA2727862C (en) | 2008-06-17 | 2016-04-19 | Millennium Pharmaceuticals, Inc. | Boronate ester compounds and pharmaceutical compositions thereof |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| PA8850301A1 (es) | 2008-11-26 | 2010-07-27 | Abbott Lab | Nuevas octahidrociclopenta[c]pirrol-4-aminas sustituidas como bloqueantes de los canales de calcio |
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| EP2376072A1 (en) | 2008-12-29 | 2011-10-19 | Tartu Ülikool (University Of Tartu) | Arginase inhibitors for the treatment of depression |
| SI2389352T1 (sl) | 2009-01-26 | 2019-08-30 | The Trustees Of The University Of Pennsylvania, Center For Technology Transfer | Inhibitorji arginaze in postopki uporabe |
| EP2473531A4 (en) | 2009-09-03 | 2013-05-01 | Merck Sharp & Dohme | Anti-gitr antibodies |
| PH12012500881A1 (en) | 2009-12-10 | 2017-07-26 | Hoffmann La Roche | Antibodies binding preferentially human csf1r extracellular domain 4 and their use |
| CN102918061B (zh) | 2010-03-05 | 2016-06-08 | 霍夫曼-拉罗奇有限公司 | 针对人csf-1r的抗体及其用途 |
| CA2789076C (en) | 2010-03-05 | 2017-11-21 | F. Hoffmann-La Roche Ag | Antibodies against human colony stimulating factor-1 receptor and uses thereof |
| CN103068830B (zh) | 2010-04-22 | 2016-06-29 | 马尔斯公司 | 精氨酸酶抑制剂及其治疗应用 |
| MX378336B (es) | 2010-05-04 | 2025-03-10 | Five Prime Therapeutics Inc | Anticuerpos que se unen a factor estimulante de colonias 1 (csf1r). |
| PT2614082T (pt) | 2010-09-09 | 2018-12-03 | Pfizer | Moléculas de ligação a 4-1bb |
| DK2632927T3 (en) | 2010-10-26 | 2016-04-11 | Mars Inc | Boronates AS ARGINSASEINHIBITORER |
| CA2824599C (en) | 2010-12-31 | 2020-03-10 | Astrazeneca Uk Limited | Arginase inhibitors and methods of use thereof |
| KR101970025B1 (ko) | 2011-04-20 | 2019-04-17 | 메디뮨 엘엘씨 | Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들 |
| US9266908B2 (en) | 2011-10-19 | 2016-02-23 | Mars, Incorporated | Inhibitors of arginase and their therapeutic applications |
| HRP20201595T1 (hr) | 2011-11-28 | 2020-12-11 | Merck Patent Gmbh | Anti-pd-l1 protutijela i njihova uporaba |
| BR112014012624A2 (pt) | 2011-12-15 | 2018-10-09 | F Hoffmann-La Roche Ag | anticorpos, composição farmacêutica, ácido nucleico, vetores de expressão, célula hospedeira, método para a produção de um anticorpo recombinante e uso do anticorpo |
| RU2014136332A (ru) | 2012-02-06 | 2016-03-27 | Дженентек, Инк. | Композиции и способы применения ингибиторов csf1r |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| CA2870526C (en) | 2012-04-18 | 2020-05-05 | Mars, Incorporated | Ring constrained analogs as arginase inhibitors |
| EP2847220A1 (en) | 2012-05-11 | 2015-03-18 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| WO2014007831A1 (en) | 2012-07-06 | 2014-01-09 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules |
| CN107759690A (zh) | 2012-08-31 | 2018-03-06 | 戊瑞治疗有限公司 | 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法 |
| US9688671B2 (en) | 2013-06-12 | 2017-06-27 | Viamet Pharmaceuticals, Inc. | Metalloenzyme inhibitor compounds |
| JP6532480B2 (ja) | 2014-04-15 | 2019-06-19 | ダウ アグロサイエンシィズ エルエルシー | 殺真菌剤としての金属酵素阻害剤化合物 |
| CL2014002403A1 (es) | 2014-09-11 | 2015-01-09 | Univ Pontificia Catolica Chile | Metodo para la preparacion enantioselectiva y purificacion del acido 2(s)-amino-6-boronohexanoico (abh) a partir de la disolucion de bpb-ni-gly en tetrahidrofurano, neutralizacion y posterior extraccion con diclorometano, disolucion en un alcohol c1-c5, enfriamiento para lograr la precipitacion de bpb, obtencion de abh y su posterior purificacion. |
| JO3579B1 (ar) | 2014-09-26 | 2020-07-05 | Luc Therapeutics Inc | مُعدِلات تفاغرية سالبة لمستقبل nr2b من المركب n-ألكيل أريل-5-أوكسي أريل-ثامن هيدرو-خماسي الحلقة [c] بيرول |
| WO2016100555A1 (en) | 2014-12-18 | 2016-06-23 | Inception 4, Inc. | Boronic acid derivatives and uses thereof |
| PL410665A1 (pl) | 2014-12-29 | 2016-07-04 | Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością | Inhibitory arginazy oraz ich zastosowania terapeutyczne |
| KR20180021117A (ko) | 2015-06-23 | 2018-02-28 | 칼리테라 바이오사이언시즈, 인코포레이티드 | 아르기나제 활성 억제를 위한 조성물 및 방법 |
| WO2017075363A1 (en) | 2015-10-30 | 2017-05-04 | Calithera Biosciences, Inc. | Compositions and methods for inhibiting arginase activity |
| PL417066A1 (pl) * | 2016-05-04 | 2017-11-06 | Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością | Inhibitory arginazy oraz ich zastosowania terapeutyczne |
| EP3538111B1 (en) | 2016-11-08 | 2022-01-19 | Calithera Biosciences, Inc. | Arginase inhibitor combination therapies |
| KR102803660B1 (ko) | 2018-03-05 | 2025-05-02 | 브리스톨-마이어스 스큅 컴퍼니 | 페닐피롤리디논 포르밀 펩티드 2 수용체 효능제 |
| EP3810615B1 (en) * | 2018-06-20 | 2026-01-28 | Merck Sharp & Dohme LLC | Arginase inhibitors and methods of use |
-
2019
- 2019-03-04 CN CN201980017421.6A patent/CN111818928A/zh active Pending
- 2019-03-04 BR BR112020017604-4A patent/BR112020017604A2/pt unknown
- 2019-03-04 EA EA202092086A patent/EA202092086A1/ru unknown
- 2019-03-04 KR KR1020207028200A patent/KR102656571B1/ko active Active
- 2019-03-04 SG SG11202008113RA patent/SG11202008113RA/en unknown
- 2019-03-04 CA CA3091805A patent/CA3091805A1/en active Pending
- 2019-03-04 WO PCT/US2019/020507 patent/WO2019173188A1/en not_active Ceased
- 2019-03-04 PE PE2020001352A patent/PE20210452A1/es unknown
- 2019-03-04 UA UAA202006325A patent/UA127897C2/uk unknown
- 2019-03-04 AU AU2019229978A patent/AU2019229978B2/en active Active
- 2019-03-04 EP EP19764594.8A patent/EP3761992A4/en active Pending
- 2019-03-04 CR CR20200445A patent/CR20200445A/es unknown
- 2019-03-04 US US16/978,335 patent/US12054500B2/en active Active
- 2019-03-04 MX MX2020009290A patent/MX2020009290A/es unknown
- 2019-03-04 IL IL276813A patent/IL276813B2/en unknown
- 2019-03-04 MY MYPI2020004399A patent/MY205512A/en unknown
- 2019-03-04 JP JP2020546139A patent/JP7402167B2/ja active Active
-
2020
- 2020-08-28 PH PH12020551352A patent/PH12020551352A1/en unknown
- 2020-09-02 CL CL2020002271A patent/CL2020002271A1/es unknown
- 2020-09-29 ZA ZA2020/06006A patent/ZA202006006B/en unknown
- 2020-09-29 CO CONC2020/0012060A patent/CO2020012060A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PH12020551352A1 (en) | 2021-06-21 |
| ZA202006006B (en) | 2025-02-26 |
| PE20210452A1 (es) | 2021-03-08 |
| JP2021516237A (ja) | 2021-07-01 |
| JP7402167B2 (ja) | 2023-12-20 |
| CR20200445A (es) | 2021-04-27 |
| MY205512A (en) | 2024-10-24 |
| IL276813A (en) | 2020-10-29 |
| EP3761992A4 (en) | 2021-11-24 |
| CA3091805A1 (en) | 2019-09-12 |
| KR102656571B1 (ko) | 2024-04-11 |
| IL276813B1 (en) | 2024-05-01 |
| EP3761992A1 (en) | 2021-01-13 |
| AU2019229978A1 (en) | 2020-10-15 |
| US20210002306A1 (en) | 2021-01-07 |
| US12054500B2 (en) | 2024-08-06 |
| MX2020009290A (es) | 2020-09-28 |
| SG11202008113RA (en) | 2020-09-29 |
| BR112020017604A2 (pt) | 2020-12-22 |
| AU2019229978B2 (en) | 2024-05-30 |
| KR20200128117A (ko) | 2020-11-11 |
| CN111818928A (zh) | 2020-10-23 |
| IL276813B2 (en) | 2024-09-01 |
| EA202092086A1 (ru) | 2021-02-09 |
| CL2020002271A1 (es) | 2021-04-09 |
| WO2019173188A1 (en) | 2019-09-12 |
| UA127897C2 (uk) | 2024-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2020012060A2 (es) | Inhibidores de la arginasa | |
| UY38476A (es) | Inhibidores de arg1 y/o arg2 | |
| PH12021500014A1 (en) | Fused ring compounds | |
| DOP2022000194A (es) | Compuestos de tetralina y tetrahidroquinolina como inhibidores de hif-2alfa | |
| MX2025002975A (es) | Compuestos de anillo fusionado | |
| JOP20230272A1 (ar) | مركبات تثبيط rip1 وطرق لتحضير واستخدامها | |
| CO2022001210A2 (es) | Conjugados de il-2 y métodos de uso para tratar enfermedades autoinmunes | |
| CO2019007863A2 (es) | Derivados de benzooxazol como inmunomoduladores | |
| CL2017001124A1 (es) | Agentes inmunomoduladores | |
| CO2019000386A2 (es) | Compuestos heterocíclicos como inmunomoduladores | |
| MX2021007146A (es) | Moduladores de la via de estres integrada. | |
| AU2017261336A1 (en) | Modulators of the integrated stress pathway | |
| BR112016028255A2 (pt) | agentes imunorreguladores | |
| AU2017260374A1 (en) | Modulators of the integrated stress pathway | |
| BR112022000855A2 (pt) | Moduladores de nlrp3 | |
| MX2022000646A (es) | Derivados de n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-4 ,5,6,7- tetrahidrobenzofuran-2-sulfonamida y compuestos relacionados como moduladores de nlpr3 para el tratamiento de esclerosis múltiple (ms). | |
| MX2020008125A (es) | Composiciones que comprenden berberina. | |
| ECSP21003171A (es) | Dinucleótidos cíclicos como agonistas de sting | |
| SA520420261B1 (ar) | تركيبات إرنوماب واستخداماتها | |
| PH12019500570A1 (en) | Ketone inhibitors of lysine gingipain | |
| MX2021003888A (es) | Nuevos compuestos utiles para el tratamiento de enfermedades cardiovasculares. | |
| CL2022003206A1 (es) | Compuestos derivados de quinolona y su uso para el tratamiento del cáncer (div. sol. 202102501) | |
| ZA202507396B (en) | Fused ring compounds | |
| EA202190409A1 (ru) | ЗАМЕЩЕННЫЕ 4-АМИНО-1H-ИМИДАЗО[4,5-c]ХИНОЛИНОВЫЕ СОЕДИНЕНИЯ И УЛУЧШЕННЫЕ СПОСОБЫ ИХ ПОЛУЧЕНИЯ | |
| EA201991524A1 (ru) | Производные бензоксазола в качестве иммуномодуляторов |